X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8797) 8797
Book Review (1205) 1205
Publication (909) 909
Newsletter (681) 681
Conference Proceeding (248) 248
Book Chapter (40) 40
Newspaper Article (28) 28
Dissertation (19) 19
Magazine Article (11) 11
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
erlotinib (7444) 7444
index medicus (6059) 6059
humans (5929) 5929
oncology (4748) 4748
gefitinib (3397) 3397
female (3055) 3055
lung neoplasms - drug therapy (3009) 3009
male (2771) 2771
erlotinib hydrochloride (2703) 2703
chemotherapy (2643) 2643
carcinoma, non-small-cell lung - drug therapy (2580) 2580
cancer (2469) 2469
middle aged (2388) 2388
aged (2243) 2243
mutation (1990) 1990
lung cancer, non-small cell (1902) 1902
receptor, epidermal growth factor - antagonists & inhibitors (1863) 1863
quinazolines - therapeutic use (1751) 1751
lung cancer (1735) 1735
lung neoplasms - genetics (1645) 1645
lung neoplasms - pathology (1616) 1616
adult (1612) 1612
receptor, epidermal growth factor - genetics (1599) 1599
antineoplastic agents - therapeutic use (1574) 1574
protein kinase inhibitors - therapeutic use (1571) 1571
care and treatment (1525) 1525
egfr (1495) 1495
epidermal growth factor (1426) 1426
cell lung-cancer (1322) 1322
carcinoma, non-small-cell lung - genetics (1319) 1319
growth-factor receptor (1281) 1281
research (1271) 1271
treatment outcome (1265) 1265
carcinoma, non-small-cell lung - pathology (1234) 1234
respiratory system (1211) 1211
non-small cell lung cancer (1115) 1115
aged, 80 and over (1109) 1109
open-label (1099) 1099
antineoplastic combined chemotherapy protocols - therapeutic use (1053) 1053
adenocarcinoma (1010) 1010
quinazolines - administration & dosage (970) 970
cell line, tumor (965) 965
therapy (955) 955
animals (946) 946
analysis (905) 905
quinazolines - pharmacology (886) 886
epidermal growth factor receptor (872) 872
tyrosine kinase inhibitors (870) 870
tyrosine kinase inhibitor (857) 857
survival (848) 848
tyrosine (821) 821
mutations (817) 817
prognosis (807) 807
acquired-resistance (802) 802
1st-line treatment (800) 800
respiratory tract diseases (794) 794
protein kinase inhibitors - pharmacology (791) 791
receptor, epidermal growth factor - metabolism (782) 782
disease-free survival (772) 772
quinazolines - adverse effects (763) 763
nsclc (761) 761
tumors (761) 761
pharmacology & pharmacy (756) 756
genetic aspects (745) 745
drug therapy (742) 742
antineoplastic agents - pharmacology (718) 718
neoplasm staging (715) 715
adenocarcinoma - drug therapy (689) 689
lung neoplasms - mortality (688) 688
bevacizumab (679) 679
hematology, oncology and palliative medicine (673) 673
trial (669) 669
metastasis (660) 660
cetuximab (648) 648
multicenter (641) 641
phase-iii trial (637) 637
mice (618) 618
carcinoma, non-small-cell lung - mortality (606) 606
expression (606) 606
health aspects (595) 595
resistance (581) 581
clinical trials (579) 579
gemcitabine (565) 565
cancer therapies (558) 558
retrospective studies (549) 549
medicine & public health (524) 524
kinases (510) 510
article (497) 497
protein kinase inhibitors - adverse effects (496) 496
antineoplastic agents - adverse effects (494) 494
oncology, experimental (493) 493
lung neoplasms - metabolism (488) 488
combination (485) 485
egfr mutations (485) 485
non-small-cell lung cancer (476) 476
patients (475) 475
lung cancer, small cell (470) 470
egfr mutation (453) 453
pancreatic cancer (452) 452
protein kinase inhibitors - administration & dosage (451) 451
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9258) 9258
French (165) 165
German (85) 85
Chinese (77) 77
Japanese (49) 49
Korean (41) 41
Spanish (39) 39
Portuguese (14) 14
Czech (12) 12
Hungarian (10) 10
Polish (8) 8
Turkish (8) 8
Dutch (5) 5
Italian (5) 5
Russian (3) 3
Danish (2) 2
Norwegian (2) 2
Croatian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Diagnosis & Therapy, ISSN 1177-1062, 01/2013, Volume 17, Issue 1, p. 57
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 55, pp. 131 - 139
Abstract Aim The aim of this study was to investigate if biomarkers of individual drug metabolism, respectively, the erlotinib/O-desmethyl-erlotinib metabolic... 
Hematology, Oncology and Palliative Medicine | Erlotinib/O-desmethyl-erlotinib ratio | EGFR inhibitor-induced skin rash | Erlotinib metabolic ratio | Predictive biomarker | PLUS GEMCITABINE | MANAGEMENT | PANCREATIC-CANCER | PHASE-III | TOXICITY | CELL LUNG-CANCER | THERAPY | PHARMACOKINETICS | ONCOLOGY | RECEPTOR TYROSINE KINASE | ADVERSE EVENTS | Exanthema - diagnosis | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Protein Kinase Inhibitors - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Erlotinib Hydrochloride - adverse effects | Lung Neoplasms - enzymology | Erlotinib Hydrochloride - pharmacokinetics | Adenocarcinoma - blood | Pancreatic Neoplasms - pathology | Adenocarcinoma - drug therapy | Disease Progression | Protein Kinase Inhibitors - blood | Erlotinib Hydrochloride - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Carcinoma, Non-Small-Cell Lung - enzymology | Germany | Lung Neoplasms - pathology | Pancreatic Neoplasms - drug therapy | Drug Dosage Calculations | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Biotransformation | Adult | Female | Pancreatic Neoplasms - mortality | Carcinoma, Non-Small-Cell Lung - pathology | Severity of Illness Index | Pancreatic Neoplasms - blood | Dealkylation | Adenocarcinoma - enzymology | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Pancreatic Neoplasms - enzymology | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - blood | Aged | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Epidermal growth factor | Erlotinib | Skin care products | Physiological aspects | Rash (Dermatology) | Skin | Biological markers | Index Medicus
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2016, Volume 34, Issue 33, pp. 4054 - U187
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | CLATHRIN-MEDIATED ENDOCYTOSIS | CELLS | DRUG-DELIVERY | CHITOSAN | TUMOR | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | PACLITAXEL | NANOPARTICLES | ENHANCED PERMEABILITY | CANCER-TREATMENT | PHARMACOLOGY & PHARMACY | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 3/2019, Volume 53, Issue 3, pp. 321 - 322
Journal Article
Cancer Discovery, ISSN 2159-8274, 2014, Volume 4, Issue 5, pp. 606 - 619
Journal Article
by Wu, Yi-Long and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of Oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
Biomaterials, ISSN 0142-9612, 11/2017, Volume 145, pp. 56 - 71
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2016, Volume 34, Issue 33, pp. 4055 - U190
Journal Article
Therapeutic drug monitoring, ISSN 0163-4356, 12/2018, Volume 40, Issue 6, pp. 699 - 704
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2016, Volume 22, Issue 7, pp. 1827 - 1827
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 10/2017, Volume 27, Issue 19, pp. 4552 - 4557
Molecular imaging using radiolabeled Tyrosine Kinase Inhibitors (TKI) is a promising strategy for detection and staging of EGFR-positive cancers. A novel... 
Erlotinib | Tyrosine Kinase Inhibitors | PET imaging | 68Ga | p-NCS-Bn-NOTA | EGFR | 68Ga-NOTA-Erlotinib | Ga-NOTA-Erlotinib | Index Medicus
Journal Article
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 07/2009, Volume 19, Issue 5, pp. 929 - 933
Journal Article